CORMEDIX INC. Debt Securities, Available-for-sale, Amortized Cost
CORMEDIX INC. (CRMD) had Debt Securities, Available-for-sale, Amortized Cost of $8.50 million as of 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Credit Loss, Additional Improvements
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $8.50M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $8.41M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $64.94M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $34.51M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-12-31 | $8.50M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $8.41M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $64.94M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $34.51M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $34.16M 10-K · filed 2026-03-05 | $34.15M 10-K · filed 2025-03-25 |
| 2024-09-30 | $33.76M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $38.30M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $51.72M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $64.92M 10-K · filed 2025-03-25 | |
| 2023-09-30 | $39.33M 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $22.96M 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |